Valganciclovir is effective prophylaxis for CMV in high risk renal transplant recipients.

被引：0
|
作者：
Baillie, GM [1 ]
Ashcraft, EE [1 ]
Taber, DJ [1 ]
Stone, SS [1 ]
Emovon, O [1 ]
Rogers, J [1 ]
Afzal, F [1 ]
Lin, A [1 ]
Rajagopalan, PR [1 ]
Baliga, PK [1 ]
Chavin, KD [1 ]
机构：
[1] Med Univ S Carolina, Div Transplant Surg, Charleston, SC 29425 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：377A / 377A
页数：1
相关论文
共 50 条
  • [41] Rates of CMV Infection in Kidney Transplant Recipients Who Received Subtherapeutic Valganciclovir Prophylaxis
    Belfield, K.
    Cohen, E.
    Malinis, M.
    Baghban, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 514 - 514
  • [42] Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients
    Inger Johansson
    Gunnar Mårtensson
    Ulla Nyström
    Salmir Nasic
    Rune Andersson
    BMC Infectious Diseases, 13
  • [43] Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients
    Kletzmayr, J
    Kotzmann, H
    PopowKraupp, T
    Kovarik, J
    Klauser, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (02): : 325 - 330
  • [44] Effectiveness of Valganciclovir Cytomegalovirus Prophylaxis Protocol in High-Risk Liver Transplant Recipients
    Shivega, W. Gaya
    Samhan, Aya
    Bolognese, Alexandra
    Enestvedt, Kristian
    Maynard, Erin
    Orloff, Susan
    Scott, David
    Woodland, David
    Olyaei, Ali
    Connelly, Christopher
    AMERICAN JOURNAL OF TRANSPLANTATION, 2024, 24 (01) : S51 - S51
  • [45] Incidence of CMV Viremia and Disease in Renal Transplant Recipients Utilizing Universal Fixed Low-Dose Valganciclovir Prophylaxis
    Knight, R. J.
    Hong, D.
    Patel, S. J.
    DeVos, J. M.
    Gaber, A. O.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 470 - 470
  • [46] Low dose valganciclovir in liver transplant recipients.
    Dupuis, R
    Harris, M
    Andreoni, K
    Gerber, D
    Conoley, R
    Fair, J
    VanBeuge, D
    Johnson, M
    Watson, R
    Shrestha, R
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 167 - 167
  • [47] Efficacy of Letermovir for CMV Prophylaxis in Heart Transplant Recipients with Moderate to High Risk CMV Serostatus
    Lee, C.
    Rahman, S.
    Baranowska, J.
    Moeller, C. M.
    Valledor, A. Fernandez
    Rubenstein, G.
    Oren, D.
    Oh, K.
    Bae, D.
    Raikhelkar, J.
    Lotan, D.
    DeFilippis, E. M.
    Theodoropoulos, K.
    Fried, J.
    Clerkin, K.
    Latif, F.
    Topkara, V.
    Yuzefpolskaya, M.
    Colombo, P.
    Lin, E.
    Majure, D.
    Sayer, G.
    Uriel, N.
    Choe, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S519 - S519
  • [48] Valganciclovir prophylaxis for cytomegalovirus disease in kidney and simultaneous pancreas-kidney transplant recipients.
    Ciancio, G
    Burke, G
    Suzart, K
    Vaidya, A
    Roth, D
    Kupin, W
    Mattiazzi, A
    Miller, J
    JOURNAL OF UROLOGY, 2002, 167 (04): : 371 - 371
  • [49] Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis
    Akalin, E
    Sehgal, V
    Ames, S
    Hossain, S
    Daly, L
    Barbara, M
    Bromberg, JS
    AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (06) : 731 - 735
  • [50] Efficacy of Two Valganciclovir Dosing Strategies in Intermediate and High-Risk Liver Transplant Recipients.
    Belfield, K.
    Malinis, M.
    Cohen, E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 878 - 878
12345